Cargando…

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations

Since 2011, with the approval of crizotinib and subsequent approval of four additional targeted therapies, anaplastic lymphoma kinase (ALK) inhibitors have become important treatments for a subset of patients with lung cancer. Each generation of ALK inhibitor showed improvements in terms of central...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, Brion W., Zhai, Dayong, Deng, Wei, Zhang, Xin, Ung, Jane, Nguyen, Vivian, Zhang, Han, Barrera, Maria, Parra, Ana, Cowell, Jessica, Lee, Dong J., Aloysius, Herve, Rogers, Evan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	MCT First Disclosures
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398166/ https://www.ncbi.nlm.nih.gov/pubmed/34158340 http://dx.doi.org/10.1158/1535-7163.MCT-21-0221

Ejemplares similares

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
por: Roulston, Anne, et al.
Publicado: (2022)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
por: Mazahreh, Rebecca, et al.
Publicado: (2023)

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
por: Deng, Jiaojiao, et al.
Publicado: (2021)

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
por: Smith, Bryan D., et al.
Publicado: (2021)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
por: Zimmermann, Astrid, et al.
Publicado: (2022)

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
por: Darvishi, Emad, et al.
Publicado: (2022)

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
por: Rigby, Michael, et al.
Publicado: (2022)

Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
por: Li, Xiaofan, et al.
Publicado: (2023)

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
por: Rossmueller, Gregor, et al.
Publicado: (2023)

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
por: Kong, Chao, et al.
Publicado: (2023)

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
por: Toader, Dorin, et al.
Publicado: (2023)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2021)

Disclosures
Publicado: (2016)

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

EHMTI-0131. Clinical features of cluster headache in women
por: Tassorelli, C, et al.
Publicado: (2014)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
por: Bauer, Todd M., et al.
Publicado: (2020)

Conflict of Interest Disclosures
Publicado: (2017)

Conflict of Interest Disclosures
Publicado: (2018)

Conflict of Interest Disclosures
Publicado: (2019)

Conflict of Interest Disclosures
Publicado: (2021)

Conflict of Interest Disclosures
Publicado: (2022)

Conflict of Interest Disclosures
Publicado: (2023)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
por: Tanaka, Makito, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
por: Gadgeel, Shirish, et al.
Publicado: (2018)

Emerging Roles of ALK in Immunity and Insights for Immunotherapy
por: Wang, Lan, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h8tdnuh5mruvpol3atdekh6aro